Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02360800
NCT02360800
Completed
Not Applicable

Randomized Prospective Comparison of Tisseel Or Control to Diminish Blood Loss After Redo Redo Cardiac Surgery: the Study

Cardiochirurgia E.H.1 site in 1 country120 target enrollmentFebruary 2, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHemorrhage

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemorrhage
Sponsor
Cardiochirurgia E.H.
Enrollment
120
Locations
1
Primary Endpoint
Bleeding (Amount of blood (ml) collected in chest drainage)
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Bleeding after redo cardiac surgery is a common, unresolved and consequences-heavy event as per present day. Tisseel (Baxter inc) sprayed on the already hemostased mediastinum jut before closing seems a promising technique to radically diminish bleeding.

This study aims to verify this efficacy volume in chest drains) and possibly the consensual blood transfusion lessening.

Registry
clinicaltrials.gov
Start Date
February 2, 2017
End Date
September 16, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Cardiochirurgia E.H.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •All patients undergoing any kind of redo cardiac surgery with ati least one previous sternotomy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Bleeding (Amount of blood (ml) collected in chest drainage)

Time Frame: first 24 hours after surgery

Amount of blood (ml) collected in chest drainage in the first 24 hours after operation

Secondary Outcomes

  • Allogeneic blood Sparing (Amount of Allogeneic Blood units (number) transfused in the first 4 days after surgery)(4 days after surgery)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
A Randomized Comparison of Two Doses of Tranexamic Acid in Open-Heart SurgeryDrug Use
NCT04996368Shahid Gangalal National Heart Centre120
Terminated
Not Applicable
A Pre-market, Multi-center, International, Double-blind, Randomized, Two-arms, Controlled, Prospective Clinical Investigation Assessing the Safety and Performance of a Medical Device (ClearPlasma™) for the Treatment of Patients Undergoing Coronary Artery Bypass or Valve ReplacementBleedingBypass ComplicationValve Replacement
NCT05542277PlasFree Ltd.130
Completed
Not Applicable
Prevention of Retained-Blood Outcomes With Active Clearance TechnologyHemorrhageAtrial Fibrillation, Postoperative
NCT02145858ClearFlow, Inc.891
Terminated
Phase 2
Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac SurgeryCardiac Surgical ProceduresCardiopulmonary BypassBlood Platelet DisordersBlood Coagulation Disorders
NCT00359398Royal Brompton & Harefield NHS Foundation Trust30
Recruiting
Phase 3
Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac SurgeryNew Onset Atrial FibrillationComplications; Cardiac, Postoperative
NCT05169866Beijing Anzhen Hospital274